Literature DB >> 21785538

Naltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults.

Tehane Ornellas, Benjamin Chavez.   

Abstract

Entities:  

Year:  2011        PMID： 21785538      PMCID： PMC3138366     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  5 in total

1.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich
Journal:  Lancet       Date:  2010-07-29       Impact factor: 79.321

2.  Body-mass index and mortality among 1.46 million white adults.

Authors:  Amy Berrington de Gonzalez; Patricia Hartge; James R Cerhan; Alan J Flint; Lindsay Hannan; Robert J MacInnis; Steven C Moore; Geoffrey S Tobias; Hoda Anton-Culver; Laura Beane Freeman; W Lawrence Beeson; Sandra L Clipp; Dallas R English; Aaron R Folsom; D Michal Freedman; Graham Giles; Niclas Hakansson; Katherine D Henderson; Judith Hoffman-Bolton; Jane A Hoppin; Karen L Koenig; I-Min Lee; Martha S Linet; Yikyung Park; Gaia Pocobelli; Arthur Schatzkin; Howard D Sesso; Elisabete Weiderpass; Bradley J Willcox; Alicja Wolk; Anne Zeleniuch-Jacquotte; Walter C Willett; Michael J Thun
Journal:  N Engl J Med       Date:  2010-12-02       Impact factor: 91.245

3.  Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

Authors:  Thomas A Wadden; John P Foreyt; Gary D Foster; James O Hill; Samuel Klein; Patrick M O'Neil; Michael G Perri; F Xavier Pi-Sunyer; Cheryl L Rock; Janelle S Erickson; Holly N Maier; Dennis D Kim; Eduardo Dunayevich
Journal:  Obesity (Silver Spring)       Date:  2010-06-17       Impact factor: 5.002

4.  Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.

Authors:  Frank L Greenway; Eduardo Dunayevich; Gary Tollefson; Janelle Erickson; Maria Guttadauria; Ken Fujioka; Michael A Cowley
Journal:  J Clin Endocrinol Metab       Date:  2009-10-21       Impact factor: 5.958

Review 5.  Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.

Authors: 
Journal:  Drugs R D       Date:  2010
  5 in total
  14 in total

Review 1.  Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.

Authors:  Marcelo O Dietrich; Tamas L Horvath
Journal:  Nat Rev Drug Discov       Date:  2012-08-03       Impact factor: 84.694

2.  Low-level laser therapy for weight reduction: a randomized pilot study.

Authors:  Ivana T Croghan; Ryan T Hurt; Darrell R Schroeder; Shawn C Fokken; Michael D Jensen; Matthew M Clark; Jon O Ebbert
Journal:  Lasers Med Sci       Date:  2019-08-31       Impact factor: 3.161

Review 3.  Targeting adipose tissue in the treatment of obesity-associated diabetes.

Authors:  Christine M Kusminski; Perry E Bickel; Philipp E Scherer
Journal:  Nat Rev Drug Discov       Date:  2016-06-03       Impact factor: 84.694

4.  Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.

Authors:  Larissa J Mooney; Maureen P Hillhouse; Christie Thomas; Alfonso Ang; Gaurav Sharma; Garth Terry; Linda Chang; Robrina Walker; Madhukar Trivedi; David Croteau; Steven Sparenborg; Walter Ling
Journal:  J Addict Med       Date:  2016 Jul-Aug       Impact factor: 3.702

5.  Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures.

Authors:  Angeliki Siamidi; Aikaterini Dedeloudi; Marilena Vlachou
Journal:  Polymers (Basel)       Date:  2021-04-30       Impact factor: 4.329

Review 6.  Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.

Authors:  Assumpta Caixàs; Lara Albert; Ismael Capel; Mercedes Rigla
Journal:  Drug Des Devel Ther       Date:  2014-09-18       Impact factor: 4.162

7.  Weight loss medications in Canada - a new frontier or a repeat of past mistakes?

Authors:  Sean Wharton; Jasmine Lee; Rebecca Ag Christensen
Journal:  Diabetes Metab Syndr Obes       Date:  2017-10-04       Impact factor: 3.168

Review 8.  Phentermine and topiramate for the management of obesity: a review.

Authors:  Gina Cosentino; Ariane O Conrad; Gabriel I Uwaifo
Journal:  Drug Des Devel Ther       Date:  2011-04-05       Impact factor: 4.162

9.  Tobacco withdrawal increases junk food intake: The role of the endogenous opioid system.

Authors:  Justin J Anker; Motohiro Nakajima; Susan Raatz; Sharon Allen; Mustafa al'Absi
Journal:  Drug Alcohol Depend       Date:  2021-06-18       Impact factor: 4.852

10.  Model-Based Approach to Predict Adherence to Protocol During Antiobesity Trials.

Authors:  Vishnu D Sharma; François P Combes; Majid Vakilynejad; Gezim Lahu; Lawrence J Lesko; Mirjam N Trame
Journal:  J Clin Pharmacol       Date:  2017-08-31       Impact factor: 3.126
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.